Cargando…

Minimally-invasive debulking of ovarian cancer in the rat pelvis by means of photodynamic therapy using the pegylated photosensitizer PEG-m-THPC

Interstitial photodynamic therapy (PDT) using the pegylated photosensitizer PEG-m-THPC was evaluated as a minimally-invasive procedure to selectively debulk unrespectable pelvic ovarian cancer (NuTu-19) in immunocompetent rats. To assess tumour selectivity, PEG-m-THPC at dosages of 0.3, 3.0 and 30 m...

Descripción completa

Detalles Bibliográficos
Autores principales: Hornung, R, Fehr, M K, Monti-Frayne, J, Tromberg, B J, Berns, M W, Tadir, Y
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1999
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2362885/
https://www.ncbi.nlm.nih.gov/pubmed/10574248
http://dx.doi.org/10.1038/sj.bjc.6690740
_version_ 1782153565571121152
author Hornung, R
Fehr, M K
Monti-Frayne, J
Tromberg, B J
Berns, M W
Tadir, Y
author_facet Hornung, R
Fehr, M K
Monti-Frayne, J
Tromberg, B J
Berns, M W
Tadir, Y
author_sort Hornung, R
collection PubMed
description Interstitial photodynamic therapy (PDT) using the pegylated photosensitizer PEG-m-THPC was evaluated as a minimally-invasive procedure to selectively debulk unrespectable pelvic ovarian cancer (NuTu-19) in immunocompetent rats. To assess tumour selectivity, PEG-m-THPC at dosages of 0.3, 3.0 and 30 mg kg(−1) body weight was administered intravenously to 30 rats 4 weeks following tumour induction. Eight days later laser light at 652 nm and optical doses ranging from 100 to 900 J cm(−1) diffuser-length was delivered by an interstitial cylindrical diffusing fibre inserted blindly into the pelvis. Three days following light application, the volume of necrosis was measured and the damage to pelvic organs was assessed histologically on cross sections. For analysis of survival, 20 tumour-bearing rats received PDT using drug doses of 3 or 9 mg kg(−1) body weight and an optical dose of 900 J cm(−1) diffuser-length, whereas ten untreated tumour-bearing rats served as controls. The histological assessment of PDT induced necrosis showed a non-linear dose–response for both the photosensitizer dose and the optical dose. The lowest drug dose activated with the highest optical dose did not induce more necrosis than seen in tumour-bearing control animals. The same optical dose induced necrosis of 17 mm in diameter using 30 mg kg(−1) and 11 mm using 3 mg kg(−1) photosensitizer. The optical threshold for induction of significant necrosis was between 100 and 300 J cm(−1) diffuser-length for 30 mg kg(−1) and between 300 and 500 J cm(−1) for 3 mg kg(−1) PEG-m-THPC. Significant damage to normal pelvic organs was only seen if 30 mg kg(−1) photosensitizer was activated with optical doses of 700 J cm(−1) or more. In the survival study, all treated animals survived PDT for at least 2 weeks and the intestinal and urinary tract remained functional. No clinical signs of blood vessel or nerve injury were observed. Mean overall survival of untreated tumour-bearing rats was 25.0 ± 4.5 days compared to 38.4 ± 3.8 days and 40.0 ± 3.6 days for rats treated with 3 mg kg(−1) or 9 mg kg(−1) PEG-m-THPC mediated PDT respectively (P < 0.05). We conclude that PEG-m-THPC mediated PDT has a favourable therapeutic window and that this minimally-invasive procedure can reduce pelvic cancer bulks effectively and selectively. © 1999 Cancer Research Campaign
format Text
id pubmed-2362885
institution National Center for Biotechnology Information
language English
publishDate 1999
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-23628852009-09-10 Minimally-invasive debulking of ovarian cancer in the rat pelvis by means of photodynamic therapy using the pegylated photosensitizer PEG-m-THPC Hornung, R Fehr, M K Monti-Frayne, J Tromberg, B J Berns, M W Tadir, Y Br J Cancer Regular Article Interstitial photodynamic therapy (PDT) using the pegylated photosensitizer PEG-m-THPC was evaluated as a minimally-invasive procedure to selectively debulk unrespectable pelvic ovarian cancer (NuTu-19) in immunocompetent rats. To assess tumour selectivity, PEG-m-THPC at dosages of 0.3, 3.0 and 30 mg kg(−1) body weight was administered intravenously to 30 rats 4 weeks following tumour induction. Eight days later laser light at 652 nm and optical doses ranging from 100 to 900 J cm(−1) diffuser-length was delivered by an interstitial cylindrical diffusing fibre inserted blindly into the pelvis. Three days following light application, the volume of necrosis was measured and the damage to pelvic organs was assessed histologically on cross sections. For analysis of survival, 20 tumour-bearing rats received PDT using drug doses of 3 or 9 mg kg(−1) body weight and an optical dose of 900 J cm(−1) diffuser-length, whereas ten untreated tumour-bearing rats served as controls. The histological assessment of PDT induced necrosis showed a non-linear dose–response for both the photosensitizer dose and the optical dose. The lowest drug dose activated with the highest optical dose did not induce more necrosis than seen in tumour-bearing control animals. The same optical dose induced necrosis of 17 mm in diameter using 30 mg kg(−1) and 11 mm using 3 mg kg(−1) photosensitizer. The optical threshold for induction of significant necrosis was between 100 and 300 J cm(−1) diffuser-length for 30 mg kg(−1) and between 300 and 500 J cm(−1) for 3 mg kg(−1) PEG-m-THPC. Significant damage to normal pelvic organs was only seen if 30 mg kg(−1) photosensitizer was activated with optical doses of 700 J cm(−1) or more. In the survival study, all treated animals survived PDT for at least 2 weeks and the intestinal and urinary tract remained functional. No clinical signs of blood vessel or nerve injury were observed. Mean overall survival of untreated tumour-bearing rats was 25.0 ± 4.5 days compared to 38.4 ± 3.8 days and 40.0 ± 3.6 days for rats treated with 3 mg kg(−1) or 9 mg kg(−1) PEG-m-THPC mediated PDT respectively (P < 0.05). We conclude that PEG-m-THPC mediated PDT has a favourable therapeutic window and that this minimally-invasive procedure can reduce pelvic cancer bulks effectively and selectively. © 1999 Cancer Research Campaign Nature Publishing Group 1999-10 /pmc/articles/PMC2362885/ /pubmed/10574248 http://dx.doi.org/10.1038/sj.bjc.6690740 Text en Copyright © 1999 Cancer Research Campaign https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Regular Article
Hornung, R
Fehr, M K
Monti-Frayne, J
Tromberg, B J
Berns, M W
Tadir, Y
Minimally-invasive debulking of ovarian cancer in the rat pelvis by means of photodynamic therapy using the pegylated photosensitizer PEG-m-THPC
title Minimally-invasive debulking of ovarian cancer in the rat pelvis by means of photodynamic therapy using the pegylated photosensitizer PEG-m-THPC
title_full Minimally-invasive debulking of ovarian cancer in the rat pelvis by means of photodynamic therapy using the pegylated photosensitizer PEG-m-THPC
title_fullStr Minimally-invasive debulking of ovarian cancer in the rat pelvis by means of photodynamic therapy using the pegylated photosensitizer PEG-m-THPC
title_full_unstemmed Minimally-invasive debulking of ovarian cancer in the rat pelvis by means of photodynamic therapy using the pegylated photosensitizer PEG-m-THPC
title_short Minimally-invasive debulking of ovarian cancer in the rat pelvis by means of photodynamic therapy using the pegylated photosensitizer PEG-m-THPC
title_sort minimally-invasive debulking of ovarian cancer in the rat pelvis by means of photodynamic therapy using the pegylated photosensitizer peg-m-thpc
topic Regular Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2362885/
https://www.ncbi.nlm.nih.gov/pubmed/10574248
http://dx.doi.org/10.1038/sj.bjc.6690740
work_keys_str_mv AT hornungr minimallyinvasivedebulkingofovariancancerintheratpelvisbymeansofphotodynamictherapyusingthepegylatedphotosensitizerpegmthpc
AT fehrmk minimallyinvasivedebulkingofovariancancerintheratpelvisbymeansofphotodynamictherapyusingthepegylatedphotosensitizerpegmthpc
AT montifraynej minimallyinvasivedebulkingofovariancancerintheratpelvisbymeansofphotodynamictherapyusingthepegylatedphotosensitizerpegmthpc
AT trombergbj minimallyinvasivedebulkingofovariancancerintheratpelvisbymeansofphotodynamictherapyusingthepegylatedphotosensitizerpegmthpc
AT bernsmw minimallyinvasivedebulkingofovariancancerintheratpelvisbymeansofphotodynamictherapyusingthepegylatedphotosensitizerpegmthpc
AT tadiry minimallyinvasivedebulkingofovariancancerintheratpelvisbymeansofphotodynamictherapyusingthepegylatedphotosensitizerpegmthpc